Dr Carl-Magnus Andersson has more than 35 years of experience from drug discovery and development and has held senior positions within a number of pharma and biotech companies, including AstraDraco, Acadia Pharmaceuticals, and KaroBio, where he has been responsible for the chemical and pharmaceutical sciences and also intellectual property strategies. During his career, Dr Andersson has managed the process development and manufacture of a variety of small molecules for clinical trials. He was for example lead chemist during the development of pimavanserin, now marketed as Nuplazid® in the USA. 

Dr Andersson holds a B.Sc. in Chemistry and a Ph.D. in Preparative Organic Chemistry from Lund University. He is an Associate Professor in Organic Pharmaceutical Chemistry at Uppsala University and has co-authored more than 100 scientific papers and patent applications.